WithdrawnNot Applicable

Biomarkers in Samples From Patients With Endometrial Cancer

Stopped: Not a treatment/applicable clinical trial

United States0Started 2010-01

Plain-language summary

This research study is studying biomarkers in samples from patients with endometrial cancer. Studying samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

Who can participate

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Samples available from one of the following: * GOG-0210 * Washington University School of Medicine Siteman Cancer Center

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Clinical sensitivity and specificity of epigenetic biomarkers in a cohort of blind samples (Project 2)

Timeframe: 1 month

Confirmation of CpG island loci frequently hypermethylated in EECs exhibiting recurrence (Project 2)

Timeframe: 1 month

Development of a molecular screening regimen to compliment family history risk assessment for the detection of Lynch syndrome (Project 3)

Timeframe: 1 month

Expression of candidate ERK1/2 substrates in the normal endometrium, primary endometrial cancers and endometrial cancer cell lines dependence of substrate phosphorylation on ERK (Project 4)

Timeframe: 1 month

Frequency of Lynch syndrome-related endometrial cancer and relationships between inherited and acquired DNA mismatch repair defects and clinicopathologic variables (Project 3)

Timeframe: 1 month

GSK3β inhibition as a therapeutic treatment of endometrial cancer and role of inhibiting other ERK substrates in endometrial cancer cell lines (Project 4)

Timeframe: 1 month

Trial details

NCT IDNCT01199250

SponsorGynecologic Oncology Group

Sponsor typeNETWORK

Study typeOBSERVATIONAL

Primary completion2019-05

View on ClinicalTrials.gov More Lynch Syndrome trials

Who can participate

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Samples available from one of the following: * GOG-0210 * Washington University School of Medicine Siteman Cancer Center

What they're measuring

Clinical sensitivity and specificity of epigenetic biomarkers in a cohort of blind samples (Project 2)

Timeframe: 1 month

Confirmation of CpG island loci frequently hypermethylated in EECs exhibiting recurrence (Project 2)

Timeframe: 1 month

Development of a molecular screening regimen to compliment family history risk assessment for the detection of Lynch syndrome (Project 3)

Timeframe: 1 month

Expression of candidate ERK1/2 substrates in the normal endometrium, primary endometrial cancers and endometrial cancer cell lines dependence of substrate phosphorylation on ERK (Project 4)

Timeframe: 1 month

Frequency of Lynch syndrome-related endometrial cancer and relationships between inherited and acquired DNA mismatch repair defects and clinicopathologic variables (Project 3)

Timeframe: 1 month

GSK3β inhibition as a therapeutic treatment of endometrial cancer and role of inhibiting other ERK substrates in endometrial cancer cell lines (Project 4)

Timeframe: 1 month